The response rate in this study -- the proportion of patients experiencing reduction in liver fat ≥30% -- ranged from 64% to ...

Viking Therapeutics' Phase 2b results show VK2809's efficacy in treating NASH, with significant liver fat reductions, NASH ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

The biotech’s liver-disease treatment is also viewed as best-in-class, earning it a full slate of buy ratings from analysts.

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

One of these is non-alcoholic steatohepatitis, or NASH, the fatty liver disease that affects millions of people and which is poised to be one of pharma’s next big growth areas. Novartis ramped ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Rezdiffra (resmetirom) is a once-daily, oral, liver-directed thyroid hormone receptor THR-β agonist designed to target key underlying causes of NASH. It is the first approved medication for the ...

Viking Therapeutics (VKTX) announced that final results from the company’s Phase 2b clinical trial of VK2809, the company’s novel ...